Research programme: antimicrobial therapeutics- Locus Biosciences

Drug Profile

Research programme: antimicrobial therapeutics- Locus Biosciences

Alternative Names: LBx PA01

Latest Information Update: 12 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Locus Biosciences
  • Class Antibacterials; RNA
  • Mechanism of Action Bacterial DNA inhibitors; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Bacterial infections; Pseudomonal infections

Most Recent Events

  • 12 Jan 2018 Locus Biosciences and IDbyDNA agree to co-develop diagnostic test for Pseudomonal infections
  • 12 Jan 2018 Locus plans a clinical trial of LBx PA01 for Pseudomonal infections
  • 03 Jan 2018 Early research in Pseudomonal infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top